Opendata, web and dolomites

ADiRaS

Alzheimer’s Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADiRaS project word cloud

Explore the words cloud of the ADiRaS project. It provides you a very rough idea of what is the project "ADiRaS" about.

lacks    spectroscopy    lumbar    net    reference    spinal    life    canal    diagnosis    first    50    diagnose    cerebrospinal    raman    million    performing    tomography    procedure    symptoms    plasma    population    rs    huge    ad    puncture    consists    invasive    multiple    improves    selling    device    aging    65    company    saving    earlier    solution    medical    fluid    analyzes    ameliorating    living    ht    delaying    price    quality    radioactive    suffer    disease    pain    institutionalization    positron    temporary    diagnostic    absolutely    admission    allergic    headaches    techniques    total    patient    market    pet    legs    1500    treatment    alzheimer    numbness    injected    expert    brain    screening    healthcare    affordable    patients    received    revolutionary    infections    marker    bleeding    severe    time    blood    2050    relatively    nursery    accurate    proper    expensive    scans    400    people    emission    reactions    onto    8bn   

Project "ADiRaS" data sheet

The following table provides information about the project.

Coordinator
RAMAN HEALTH TECHNOLOGIES SL 

Organization address
address: AVDA FRANCISCO VALLES 8 BIOINCUBADORA PARQUE TECNOLOGICO
city: BOECILLO VALLADOLID
postcode: 47151
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RAMAN HEALTH TECHNOLOGIES SL ES (BOECILLO VALLADOLID) coordinator 50˙000.00

Map

 Project objective

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal.

There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission.

Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADIRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADIRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More